

PRESS NOTE

Milan, 28 February 2020 - **Friulchem S.p.A.** (AIM: FCM), innovative SME and one of the main Italian operators at international level in R&D and in the production on behalf of third parties (CDMO) of semi-finished and finished products containing pharmaceutical active ingredients, dietary supplements, specialising in particular in drug delivery for the veterinary sector, in relation to the situation that has arisen as a result of the Corona Virus COVID-19 epidemic, states that, as of today, no problems were verified in terms of the production and shipping of its products, a high percentage of which is intended for the international veterinary sector. The company also declares that it has, over time, diversified its supply sources and so it has not encountered issues in the restocking of materials.

No slowdowns in business have been recorded, which is continuing as normal at the Vivaro laboratories, with extra attention focused on hygiene regulations. In addition, precautions have been taken to protect the health of employees and their families.

Friulchem expresses its solidarity for those impacted directly or indirectly by the Corona Virus COVID-19 epidemic, and hopes that the emergency ends as soon as possible.

Friulchem (AIM:FCM), a company that has been operating in this sector for over 20 years, is today one of Italy's leading CDMOs (*Contract Development Manufacturing Organisations*) operating internationally in the healthcare sector. It offers third-party research, development and manufacturing services for semi-finished and finished products containing both active pharmaceutical ingredients and food supplements. It primarily specialises in drug delivery systems for the veterinary sector, providing Friulchem's trademark excellence, as well as in the development of dossiers for generic medicines for human use. Friulchem is an innovative SME and B2B company which prides itself on its end-customer focus, and has deep Italian roots, thanks to its manufacturing facilities in Vivaro (Pordenone) and administrative headquarters in Milan. The Company is strongly oriented towards R&D activities and boasts established relationships with leading multinational companies in the pharmaceutical sector.

Common Shares ISIN: IT0005378457 - Friulchem Warrant ISIN: 2019-2022 IT0005378366

Friulchem S.p.A.

ir@friulchem.com

Tel: +39 02 36591450

Integrae SIM S.p.A. – Nominated Adviser

Giulia Mucciariello

info@integraesim.it

Tel: +39 02 87208720

CDR Communication - Investor and Media Relations

Silvia Di Rosa silvia.dirosa@cdr-communication.it

Marianna Tremolada marianna.tremolada@cdr-communication.it